Abstract:This review provides an overview of relevant aspects of retinoid physiology and molecular biology, and summarizes the current status of clinical investigations on the use of retinoid for the treatment of malignancies. The mechanism underlying the anticarcinogenic activity of retinoids appears to be associated with the ability of retinoids to modulate the growth and induce differentiation, and apoptosis of normal, premalignant, and malignant cellsin vitro andin vivo. Retinoid effects seem to be resulted from changes in gene expression mediated via specific nuclear receptors (termed retinoic acid receptors, RAR-α, -β and -γ). Chromosome translocations play an important role in APL pathogenesis. In the classical translocation, RAR a gene is fused with PML gene to form PML-RAR a chimeric gene, which is expressed in over 95% of the APL patients with t (15; 17) (q22; q21). Therefore, PML-RAR a fusion gene is the molecular marker of APL. ATRA can induce relocalization of the PML and restore the normal structure of POD. Furthermore, it could cause a degradation of PML-RAR α. In addition to the very high clinical response rate for APL patients treated with ATRA, clinical responses have been observed for patients with myelodysplastic syndrome, cutaneous T-cell lymphoma and skin cancers. Applications of retinoids are reviewed in different malignancies: including skin cancer, head and neck carcinoma, neuroblastoma, lung cancer, breast cancer, prostate cancer, bladder cancer and ovarian cancerin vivo andin vitro studies. The results indicate that retinoids are potentially useful agents for cancer prevention. RA combined with IFNs or RA combined with G-CSF has synergistic effect in inducing differentiation of cell growth. From current clinical results at least four leads are expected to impact on clinical development of retinoids in future: (1) development of retinoid receptor-selective agents; (2) investigation on cross-talk among members of the steroid superfamily; (3) strategies for attaining sufficient tissue levels of retinoids; (4) combined use with other differentiation or chemotherapeutic agents.

Retinoic Acid and Its Derivatives in Dermatological Disorders

Retinoic Acid and Its Derivatives in Skin

Retinoids and Their Applications in Clinic

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

Potential Role of Nuclear Receptor Ligand All-Trans Retinoic Acids in the Treatment of Fungal Keratitis

Molecular Interactions of Selective Agonists and Antagonists with the Retinoic Acid Receptor γ

Bexarotene: a Promising Anticancer Agent

Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia

Retinoids: Concepts for Separation of Desirable and Undesirable Effects in the Treatment or Prevention of Cancer

Multiple mechanisms: the example of vitamin A

Molecular Mechanisms of Retinoic Acid Action

The success and the challenge of all-trans retinoic acid in the treatment of cancer

Retinoids Offer New and Promising Cancer Therapeutic Avenues

Role of Retinoids and Their Analogs in the Treatment of Cutaneous T-cell Lymphoma: A Systematic Review

Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers

All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia

Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy

Cellular and micro-environmental responses influencing the antitumor activity of all-trans retinoic acid in breast cancer

Function of Retinoid Acid Receptor Α and P21 in All-Trans-retinoic Acid-Induced Acute T-lymphoblastic Leukemia Apoptosis

Retinoids in the Pathogenesis and Treatment of Liver Diseases

The retinoid X receptor has a critical role in synthetic rexinoid-induced increase in cellular all- trans -retinoic acid